BARCELONA, Spain, June 8, 2015 /PRNewswire/ --
- The goal behind the Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis is to increase awareness on this global epidemic and provide a comprehensive platform for strategic planning to tackle these two conditions.
The World Health Organization declares chronic respiratory diseases as one of the 4 major health problems of mankind. Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) affect more than 30% of the population worldwide. The socio-economic impact of chronic upper airway diseases is estimated in Europe to be more than 150 billion Euro per year.
The many unmet needs in the field of AR and CRS, identified in several domains (education, research, development and clinical care) and the huge socioeconomic burden on healthcare systems are expected to substantially increase and thus effective policy and strategy development are needed at the global, regional and national levels.
To tackle this important global health problem, the European Academy of Allergy and Clinical Immunology (EAACI) developed the Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis as part of the EAACI Global Atlas series. The Global Atlas of Asthma and the Global Atlas of Allergy were launched in 2013 and 2014, with huge success worldwide.
The Global Atlas, written by 218 world leaders in the field of AR and CRS from 38 countries, is developed as a reference for multisectoral usage. It covers all aspects of AR and CRS from epidemiology, risk factors and molecular and cellular mechanisms to their management, clinical features and co-morbidities, diagnosis, treatment, prevention and control. In addition, the Global Atlas will offer an educational tool and a reference for medical students, allied health workers, primary care physicians, pharmacists, medical industry, policy makers, patient organisations and specialists dealing with AR and CRS.
The authors of the Global Atlas are highlighting several topics that need to be addressed as a priority: the development of novel tools for evaluation of patient-specific burden of the disease, improvement of the current clinical care pathways to obtain a higher degree of control, research focused on determinants of uncontrolled and severe AR and CRS. The implementation of these actions should be supported by a higher level of education of physicians, pharmacists and patients, focusing on the benefits of proper diagnosis and adequate personalised treatment.
Full press release: https://hkstrategies.egnyte.com/fl/pN1HnM1f9o